621results about How to "Inhibit the inflammatory response" patented technology

Methods and compositions for treating or ameliorating lower back pain by administering an effective amount of one or more cell types, alone, and/or in combination with a matrix, and/or in combination with growth factors, in order to stimulate lumbar angiogenesis, decrease inflammation, and stimulating regeneration.

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal alpha 2->3 sialylation and internal alpha 1->3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.

Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

There is provided a biocompatible electrode structure which is capable of being connected to an electronic circuit, and in which a conductive nanomaterial is dispersed into a polymeric medium, in which a density of the conductive nanomaterial on an opposite side of a connection surface to the electronic circuit, in the polymeric medium is lower than that on the side of the connection surface to the electronic circuit.

The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin; 2°. exerting said inhibitory effect on inflammatory response to an external stimulus even under conditions of oxidative stress, 3°. exerting a local immuno-modulating and anti-inflammatory effect in the intestine, thus preventing intestinal damage induced by a non-steroid anti-inflammatory drug (NSAIDs), 4°. exerting an immuno-modulating and anti-inflammatory effect in human intestinal cells in vitro, 5°. alleviating pulmonary symptoms, such as shortness of breath and dyspnoea, in patients suffering from an obstructive pulmonary disease, and 6°. exerting favorable clinical effects with respect to certain mental and neurological disorders and aberrant conditions. The medicine is preferably manufactured in lyophilized form.

The invention discloses a liquid wound dressing which is characterized by comprising the following raw materials in parts by weight: 100-180 parts of a medical polymer film forming material, 0-20 parts of chitosan, 10-25 parts of polyethylene glycol 400 and 10-28 parts of glycerin, wherein the medical polymer film forming material is one in polyvinyl alcohol and polyvinyl butyral or a mixture of carbomer and one in the polyvinyl alcohol and the polyvinyl butyral. The liquid wound dressing can absorb the wound exudate, can effectively debride, maintains the surface of a wound to be wet, promotes the wound healing and is good in sterilizing effect.

The present invention relates to medicine material technology, and is especially one kind of antiphlogistic medicine and growth factor slow releasing system and its preparation process and application. The prepared nanometer fiber medicine carrying film may be used in surgical operation to resist inflammation as skin tissue engineering rack. As post-operational adhesion resisting film, the present invention is biodegradable and biocompatible and has antiphlogistic effect. At the same time, medicine is combined with growth factor in controlled release speed and used in skin tissue engineering to prevent inflammation and to release growth factor promoting skin cell regeneration and healing simultaneously. The present invention has wide application foreground in post-operational adhesion prevention and skin tissue engineering.

The invention discloses multi-effect ceramide face cream. The multi-effect ceramide face cream is prepared from a component A and a components B, wherein the component A is prepared from, by weight, 60%-80% of water, 5%-10% of mineral oil, 2%-6% of glycerin, 1%-6% of butanediol, 1%-3% of cetyl alcohol, 1%-3% of sorbitan stearate, 1%-3% of polydimethylsiloxane, 1%-2% of beewax, 0.2%-0.5% of PEG-40 stearate and 0.2%-0.5% of cetyl palmitate, and the component B is prepared from, by weight, 0.1%-0.3% of phenoxyethanol, 0.1%-0.3% of laureth-9, 0.1%-0.2% of xanthan gum, 0.05%-0.12% of propyl hydroxybenzoate, 0.05%-0.12% of methylparaben, 0.05%-0.12% of Carbomer, 0.05%-0.12% of potassium acrylates/C10-30 alkyl acrylate crosspolymer, 0.02%-0.12% of sodium hydroxide, 0.00005%-0.00015% of phenylethyl resorcinol, 0.005%-0.012% of ceramide 2 and the like. The multi-effect ceramide face cream has the effects of whitening, moisturizing, wrinkle removing, aging resisting and allergy resisting.

The present invention provides novel and inventive biodegradable and biocompatible materials and methods of use in biomedical area. Inventive materials can be formed by blending PLGA with ACP or any one of their family members. Inventive materials can be used in making biodegradable products including but not limit to drug eluting stents, vascular graft, bone substitutes such as bone fixation screws, surgical sutures and anti-adhesive membranes, and/or drug-slow release control vehicle etc.

The invention relates to an anti-allergic composition for relieving as well as an application thereof. The anti-allergic composition for relieving comprises the following components: a first anti-allergic composition, a second anti-allergic composition, an anti-allergic peptide composition, Crambe abyssinica seed oil, bisabolol, and a Cardiospermum halicacabum extract product; the active componentof the first anti-allergic composition comprises 4-tert-butylcyclohexanol and 2-(3-(4-hydroxyphenyl)propanamido)benzoic acid; the active components of the second anti-allergic composition comprise anextract product of Stephania tetrandra, potassium lactate, phenoxyethanol, and dipotassium glycyrrhizinate; the active components of the anti-allergic composition comprise palmitoyl tripeptide-8 andacetyl tetrapeptide-15. The anti-allergic composition for relieving is evaluated by a macrophage nitric oxide inflammation releasing model, inhibition rate of nitric oxide releasing reaches 46.07%, and inhibition rate of histamine reaches 61.59%.

Nucleic acid sequences and corresponding translated products of novel mutant forms of the Drosophila hid gene are described. Such sequences and products are useful in screening methods for identifying and testing antagonists of Hid phosphorylation, in particular, compositions modifying MAPK phosphorylation of Hid.

The invention discloses a non-toxic environment-friendly solvent type double-layer nanofiber skin dressing and a preparation method thereof. The non-toxic environment-friendly solvent type double-layer nanofiber skin dressing comprises a drug-loaded hydrophilic repair natural polymer fiber layer and a waterproof and breathable synthetic polymer fiber layer, and is prepared by adopting a non-toxicenvironment-friendly solvent system through an electrostatic spinning technology layer by layer. The preparation method comprises the steps that a natural polymer and a drug are dissolved in a non-toxic environment-friendly solvent, and a cross-linking agent is added; a synthetic polymer is dissolved in the non-toxic environment-friendly solvent, and a water repellent agent is added; and a naturalpolymer solution and a synthetic polymer solution are placed in an injection syringe, and an electrostatic spinning device is adopted for spinning to prepare a double-layer fiber membrane. The double-layer nanofiber skin dressing prepared through the preparation method does not contain a toxic solvent, and does not generating toxic and side effects on open wounds when serving as the dressing; andthe double-layer nanofiber skin dressing has waterproof and breathable performance, is good in cytocompatibility, can promote wound healing of rats with skin damages, and has the huge application prospects in the field of skin dressings.

A medicine coated scaffold for preventing and treating the renarrowing of arteria coronaria after plastic operation features that the tatin kind of medicines which can suppress the growth of new tunia intime and the reproduction of smooth muscle cells is contained in the coated layer of scaffold and can be slowly released to prevent said renarrowing of arteria coronaria. Its advantages are high effect and low cost.

Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.

The present invention relates to a use of a biological surfactant as an anti-inflammatory agent and a tissue preservative solution. More particularly, the present invention is directed to an anti-inflammatory agent and a tissue preservative solution comprising a biological surfactant which blocks a reaction of a proinflammatory factor with a receptor by emulsifying the proinflammatory factor.

The invention relates to the field of Chinese medicine preparation, in particular to a method for preparing tripterine nano structure lipid carrier containing traditional Chinese medicine monomer and application of the tripterine nano structure lipid carrier in preparation of transdermal drugs used for treating psoriasis, rheumatoid arthritis, skin cancer and breast cancer. The tripterine nano structure lipid carrier is characterized by comprising the following components in parts by weight: 1 part of tripterine, 5-100 parts of mixed lipid, 0.5-10 parts of phospholipid, 0.1-15 parts of poloxamer-188 and 0.5-10 parts of vitamin E and tocopherol polyethylene glycol succinate, wherein the mixed lipid is composed of solid lipid monoglycerine and liquid lipid octylic acid/caprin according to the weight ratio of 1: 0.1-10: 1. Tripterine is prepared into the nano structure lipid carrier, the tripterine nano structure lipid carrier in a semi-solid or liquid preparation form is applied in a transdermal way, bioavailability of the tripterine can be improved, toxic response of tripterine can be reduced, and the nano structure lipid carrier provided by the invention has great clinical application value in the improvement of the treatment effect of tripterine.

The present invention relates to a fusion protein composed of the extracellular domain of PD-L1 and a modified immunoglobulin Fc region. The extracellular domain of PD-L1 and a fragment thereof have excellent immunomodulatory activity, and can be used as an immunomodulatory agent if a modified immunoglobulin Fc region is coupled thereto. Accordingly, the PD-L1 fusion protein according to the present invention demonstrated its excellent effect in disease models of inflammatory bowel disease, colitis, psoriasis, asthma and arthritis, and thus can be very effectively used for the treatment of such diseases.

The present invention relates to a pure Chinese medicine preparation. Jianwei Kangning Jiaonang capsule for curing the diseases of chronic gastritis, atrophic gastritis, gastro-duodenal ulcer, bile-regurgitational gastritis, functional dyspepsia, peptic ulcer, chronic hepatitis and chronic cholecystitis with obvious therapeutic effect and high cure rate. Said medicine is made up by using 21 Chinese medicinal materials of white peony root, pinellia tuber, poria, unceria stem and thorn, alpinia fruit, fennel fruit and others.

The present invention is one kind of medicine delayed releasing blood vessel rack capable of preventing post-operation blood vessel stenosis and its preparation process. The rack consists of siphonic blood vessel rack made of Ni-Ti memory alloy or stainless steel, porous ceramic film base layer of calcium phosphate attached to the siphonic blood vessel rack, and medicine carrying degradable surface layer attached to the porous ceramic film base layer of composite biodegradable polymer and specific medicine. The preparation process includes the steps of: machining blood vessel rack with proper material; surface activation of the blood vessel rack and two-step bionic deposition; and soaking the blood vessel rack with surface porous ceramic film base layer inside the mixture solution with specific medicine, biodegradable polymer and solvent.